Brainomix 360 e-CTA

The Brainomix 360 e-CTA is a Class II medical image processing system that utilizes AI/ML algorithms to analyze CT Angiography datasets, specifically focusing on visualizing and quantifying vessel density asymmetry in the MCA region. Its development involved the integration of a novel 3D-colored overlay and was validated through digital phantom studies and a retrospective analysis of 308 brain scans, affirming its accuracy, safety, and efficacy for clinical use.

Brainomix Limited has developed the Brainomix 360 e-CTA, a Class II medical image management and processing system designed for use by trained medical professionals. This software system is intended for viewing, processing, and analyzing images obtained from DICOM-compliant imaging devices, specifically focusing on CT Angiography (CTA) datasets. Following a regulatory review, the device was deemed substantially equivalent to existing legally marketed systems, thereby making it available for clinical application under general regulatory provisions. The Brainomix 360 e-CTA's core functionality revolves around providing viewing and analysis capabilities for CTA, with a particular emphasis on identifying vessel density asymmetry within the Middle Cerebral Artery (MCA) region. Its technological foundation includes the integration of AI/ML algorithms to enhance image quality and improve vessel detection, along with features such as accessible posterior Maximum Intensity Projection (MIP) views and an innovative 3D-colored overlay for visualizing blood vessel density asymmetry. Performance was rigorously assessed through digital phantom validation and a retrospective study of 308 CTA brain scans, which collectively affirmed its accuracy in vessel and parenchyma delineation, overall effectiveness, and compliance with relevant risk management and cybersecurity standards, demonstrating both safety and efficacy.

AI Regulatory Concerns

Powered by

Jev reads the full FDA letter and returns calibrated concern probabilities per regulatory category. These are AI estimates, not regulatory advice.

• Q1. How do the AI/ML algorithms specifically enhance image quality and vessel detection compared to traditional methods?; What is the sensitivity and specificity of the Brainomix 360 e-CTA in detecting subtle vessel density asymmetry in the MCA region compared to human expert assessment?; Beyond the MCA region, can the system's vessel density asymmetry analysis be applied effectively to other cerebral vascular territories?; What are the clinical workflow implications and time-saving benefits of integrating Brainomix 360 e-CTA into an acute stroke imaging protocol?; Are there ongoing or planned prospective studies to further validate the system's impact on patient outcomes or treatment decisions?